roche qtr report tonight

I understand Roche reports tonight their Q1 results.

To recap, Tamiflop sales were 65M (CHF) in the previous quarter (Q4 2010), with 28M of that in Japan.

I'm looking for overall sales in this quarter to be better, meaning the rising tide benefits Relenza sales as well, while hoping Tamipoo's Japan sales flop or remain static, which might indicate Inavir is eating into their market share.

Basically, I am attempting to go cross eyed trying to read between the lines...